• United States

U.S. Biotech Stocks Analysis

NasdaqCM:CUE
NasdaqCM:CUE
NasdaqCM:CUEBiotechs

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

May 12, 2022
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
NasdaqCM:ATOS
NasdaqCM:ATOS
NasdaqCM:ATOSBiotechs

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

May 12, 2022
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
NasdaqGS:YMAB
NasdaqGS:YMAB
NasdaqGS:YMABBiotechs

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

May 12, 2022
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
NasdaqGM:MNOV
NasdaqGM:MNOV
NasdaqGM:MNOVBiotechs

Investors three-year losses grow to 82% as the stock sheds US$16m this past week

May 12, 2022
As an investor, mistakes are inevitable. But really bad investments should be rare. So take a moment to sympathize with...
NasdaqGM:ADVM
NasdaqGM:ADVM
NasdaqGM:ADVMBiotechs

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

May 12, 2022
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
NasdaqCM:PNT
NasdaqCM:PNT
NasdaqCM:PNTBiotechs

POINT Biopharma Global Inc.'s (NASDAQ:PNT) market cap dropped US$269m last week; individual investors who hold 40% were hit as were institutions

May 12, 2022
A look at the shareholders of POINT Biopharma Global Inc. ( NASDAQ:PNT ) can tell us which group is most powerful. And...
NasdaqCM:NBSE
NasdaqCM:NBSE
NasdaqCM:NBSEBiotechs

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

May 12, 2022
We can readily understand why investors are attracted to unprofitable companies. For example, although...
NasdaqGM:ACET
NasdaqGM:ACET
NasdaqGM:ACETBiotechs

Adicet Bio (NASDAQ:ACET shareholders incur further losses as stock declines 31% this week, taking one-year losses to 17%

May 12, 2022
Investors can approximate the average market return by buying an index fund. While individual stocks can be big...
NasdaqGS:JNCE
NasdaqGS:JNCE
NasdaqGS:JNCEBiotechs

After a 18% dip, insiders are undoubtedly glad they sold Jounce Therapeutics, Inc. (NASDAQ:JNCE)

May 12, 2022
By selling US$469k worth of Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) stock at an average sell price of US$6.88 over...
Last
  • 1
  • 2
  • 3
  • 4
  • 5
Next

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.

Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
  • About
  • Company
  • Careers
  • Plans
  • Log In
  • Help Centre
  • Latest Coverage
  • Podcasts
  • Financial Services Guide
  • Terms and Conditions
  • Privacy Policy

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.